BRAF and cholangiocarcinoma: The patient's condition improved dramatically, and he survived.<h4>Conclusion</h4>We report a rare case of cholangiocarcinoma with suspected EBV-associated HLH that developed after sequential therapy with an ICI and BRAF/MEK inhibitors.